---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003910"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:01:44.253460+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Jazz Pharma reaffirms 2023 revenue guidance; sees 2024 double-digit growth for key drugs

## Summary
- Reaffirms 2023 total, neuroscience, and oncology revenue guidance range.
- Xywav, Epidiolex, and Rylaze expected to have combined double-digit revenue growth in 2024.
- High-sodium oxybate authorized generic royalty revenue expected to grow in 2024.

## SEC filing metadata
- accession: 0001193125-24-003910
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000119312524003910/0001193125-24-003910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000119312524003910/d636118d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003910
- JSON: https://secwatch.observer/filing/0001193125-24-003910.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003910.txt

## Key facts
- Earnings Releases
  Jazz Pharmaceuticals plc updated its the year ended December 31, 2024 guidance (initiated).
  - Period: the year ended December 31, 2024
  - Guidance: initiated
  - Result: guidance update
  source text: the Company's expectations that its key growth drivers, Xywav, Epidiolex, and Rylaze, are expected to have combined double-digit percentage revenue growth in 2024, and (iii) the Company's expectations with respect to the growth of high-sodium oxybate authorized generic royalty revenue for the year ended December 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1232524/000119312524003910/0001193125-24-003910-index.htm
- Earnings Releases
  Jazz Pharmaceuticals plc updated its the year ended December 31, 2023 guidance (reaffirmed).
  - Period: the year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: guidance update
  source text: the Company's expectations that it will meet its previously announced total, neuroscience and oncology revenue guidance range for the year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1232524/000119312524003910/0001193125-24-003910-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.